Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis

Arunmozhimaran Elavarasi, Manya Prasad, Tulika Seth, Ranjit Kumar Sahoo, Karan Madan, Neeraj Nischal, Manish Soneja, Atul Sharma, Subir Kumar Maulik, Shalimar, Pramod Garg, Arunmozhimaran Elavarasi, Manya Prasad, Tulika Seth, Ranjit Kumar Sahoo, Karan Madan, Neeraj Nischal, Manish Soneja, Atul Sharma, Subir Kumar Maulik, Shalimar, Pramod Garg

Abstract

Background: There is no effective therapy for COVID-19. Hydroxychloroquine (HCQ) and chloroquine (CQ) have been used for its treatment but their safety and efficacy remain uncertain.

Objective: We performed a systematic review to synthesize the available data on the efficacy and safety of CQ and HCQ for the treatment of COVID-19.

Methods: Two reviewers searched for published and pre-published relevant articles between December 2019 and 8 June 2020. The data from the selected studies were abstracted and analyzed for efficacy and safety outcomes. Critical appraisal of the evidence was done by Cochrane risk of bias tool and Newcastle Ottawa Scale. The quality of evidence was graded as per the GRADE approach.

Results: We reviewed 12 observational and 3 randomized trials which included 10,659 patients of whom 5713 received CQ/HCQ and 4966 received only standard of care. The efficacy of CQ/HCQ for COVID-19 was inconsistent across the studies. Meta-analysis of included studies revealed no significant reduction in mortality with HCQ use [RR 0.98 95% CI 0.66-1.46], time to fever resolution (mean difference - 0.54 days (- 1.19-011)) or clinical deterioration/development of ARDS with HCQ [RR 0.90 95% CI 0.47-1.71]. There was a higher risk of ECG abnormalities/arrhythmia with HCQ/CQ [RR 1.46 95% CI 1.04 to 2.06]. The quality of evidence was graded as very low for these outcomes.

Authors' conclusion: The available evidence suggests that CQ or HCQ does not improve clinical outcomes in COVID-19. Well-designed randomized trials are required for assessing the efficacy and safety of HCQ and CQ for COVID-19.

Keywords: COVID-19; Chloroquine; SARS-CoV-2; hydroxychloroquine; meta-analysis.

Conflict of interest statement

The authors declare that they do not have a conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram for study selection.
Figure 2
Figure 2
Effect of HCQ on mortality in patients with COVID-19.
Figure 3
Figure 3
Effect of HCQ on clinical deterioration/need for mechanical ventilation in patients with COVID-19.
Figure 4
Figure 4
Effect of HCQ on virological clearance in patients with COVID-19.
Figure 5
Figure 5
Effect of HCQ on time to fever remission in patients with COVID-19.
Figure 6
Figure 6
Effect of HCQ on ECG abnormalities in patients with COVID-19.

References

    1. Coronavirus Update (Live): 7,132,732 Cases and 406,959 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet]. [cited 2020 Jun 8]. Available from: = homeAdUOA?Si,
    1. RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf [Internet]. [cited 2020 May 29]. Available from:
    1. CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Apr 28]. Available from:
    1. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
    1. Ottawa Hospital Research Institute [Internet]. [cited 2020 Jun 11]. Available from:
    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
    1. Borba MGS, Val F de A, Sampaio VS, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. 2020 Apr 16;2020.04.07.20056424.
    1. Chen X, Zhang Y, Zhu B, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou. China: a retrospective cohort study. medRxiv. 2020;14:2020.04.09.20058941.
    1. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet [Internet]. 2020 May 22 [cited 2020 May 23];0(0). Available from:
    1. Kim MS, Jang S-W, Park Y-K, et al. Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea. medRxiv. 2020 May 18;2020.05.13.20094193.
    1. Auld S, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with COVID-19. medRxiv. 2020 Apr 26;2020.04.23.20076737.
    1. Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv. 2020 May 1;2020.04.27.20073379.
    1. CHEN Jun LD, CHEN Jun LD. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ Med Sci. 2020 Mar 6;49(1):0–0.
    1. Feng Z, Li J, Yao S, et al. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv. 2020 Apr 10;2020.04.08.20057539.
    1. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
    1. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 May 7;0(0):null.
    1. Mallat J, Hamed F, Balkis M, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 2020 May 2;2020.04.27.20082180.
    1. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020 Apr 23;2020.04.16.20065920.
    1. Mahévas M, Tran V-T, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844.
    1. Huang M, Li M, Xiao F, et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. medRxiv. 2020 May 4;2020.04.26.20081059.
    1. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA [Internet]. 2020 May 11 [cited 2020 May 29]; Available from:
    1. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;14:369–m1849.
    1. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020 Apr 10;2020.03.22.20040758.
    1. Ip A, Berry DA, Hansen E, et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. medRxiv. 2020 May 25;2020.05.21.20109207.
    1. Singh S, Khan A, Chowdhry M, Chatterjee A. Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network. medRxiv. 2020 May 19;2020.05.12.20099028.
    1. Novales FJM de, Ramírez-Olivencia G, Estébanez M, et al. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. 2020 May 5 [cited 2020 Jun 13]; Available from:
    1. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020 May 11;
    1. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762.
    1. Antiviral Therapy | Coronavirus Disease COVID-19 [Internet]. COVID-19 Treatment Guidelines. [cited 2020 May 30]. Available from:
    1. Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet [Internet]. 2020 Jun 5 [cited 2020 Jun 8];0(0). Available from:
    1. Million M, Gautret P, Colson P, et al. Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big Data and the real world. New Microbes New Infect. 2020;6:100709.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner